Active Filter(s):
Details:
Microviable will use the seed funding to enhance their therapeutic development platform and advance their pipeline to the clinical stage, including lead product, MVT-201, at pre-clinical stage with positive results, and it is an unique biological drug for undisclosed targets.
Lead Product(s): MVT-201
Therapeutic Area: Infections and Infectious Diseases Product Name: MVT-201
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: Inmunomet Intolerancia y Disbiosis SL
Deal Size: $1.6 million Upfront Cash: Undisclosed
Deal Type: Financing April 19, 2022